Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box? Reply

被引：1
|
作者：
Hope, Thomas A. [1 ,2 ,3 ]
Calais, Jeremie [4 ,5 ]
机构：
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 185 Berry St,Ste 350, San Francisco, CA 94107 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] San Francisco VA Med Ctr, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA 90095 USA
[5] Univ Duisburg Essen, German Canc Consortium DKTK, Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源：
JAMA ONCOLOGY | 2022年 / 8卷 / 04期
关键词：
D O I：
10.1001/jamaoncol.2021.7994
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：644 / 645
页数：1
相关论文
共 28 条
  • [21] Maintenance treatment with oral anticancer agents after first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis
    Hu, Longfei
    Huang, Yuxin
    Zhang, Ju
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2025, 282 (02) : 589 - 595
  • [22] Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
    Han, Jiaqi
    Lan, Xiaomeng
    Tian, Kun
    Shen, Xi
    He, Jinlan
    Chen, Nianyong
    FRONTIERS IN PUBLIC HEALTH, 2023, 10
  • [23] Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy
    Peng, PeiJian
    Ou, XueQing
    Liao, Hai
    Liu, YuMeng
    Wang, SiYang
    Cheng, ZhiBin
    Lin, Zhong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (03) : 153 - 159
  • [24] Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinumbased chemotherapy: multi-institutional retrospective analysis
    Peng, Pei-Jian
    Cheng, Hua
    Ou, Xue-Qing
    Zeng, Lin-Juan
    Wu, Xuan
    Liu, Yu-Meng
    Lin, Zhong
    Tang, Yan-Na
    Wang, Si-Yang
    Zhang, Hong-Yu
    Chen, Zhi-Bin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1083 - 1087
  • [25] Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial (vol 385, e077890, 2024)
    Liu
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [26] Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens
    Peng, Pei-Jian
    Lv, Bao-Jun
    Wang, Zhi-Hui
    Liao, Hai
    Liu, Yu-Meng
    Lin, Zhong
    Con, Yun-Yan
    Huang, Pei-Yu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (02) : 68 - 74
  • [27] Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapy (DEC, 10.1007/s12094-023-03344-w, 2023)
    He, Danjie
    Zhang, Yudong
    He, Shuiqing
    Zhang, Yuzhuo
    Dai, Keyao
    Xu, Cheng
    Huang, Ying
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (05): : 1280 - 1282
  • [28] Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy A Phase 3 Randomized Clinical Trial
    Liu, Guo-Ying
    Li, Wang-Zhong
    Wang, De-Shen
    Liang, Hu
    Lv, Xing
    Ye, Yan-Fang
    Zhao, Chong
    Ke, Liang-Ru
    Lv, Shu-Hui
    Lu, Nian
    Bei, Wei-Xin
    Cai, Zhuo-Chen
    Chen, Xi
    Liang, Chi-Xiong
    Guo, Xiang
    Xia, Wei-Xiong
    Xiang, Yan-Qun
    JAMA ONCOLOGY, 2022, 8 (04) : 553 - 561
123